• In early January 2026, Structure Therapeutics’ subsidiary Gasherbrum entered a non-exclusive patent license agreement granting Genentech rights to support development and commercialization of CT-996, including a US$100,000,000 upfront payment and future royalties on net sales.
• This deal lets Genentech advance GLP-1 obesity treatment efforts while Structure retains control over its internal programs, highlighting rising industry interest in oral weight-loss therapies.
• Against this backdrop, we’ll examine how the CT-996 licensing deal with Genentech could shape Structure Therapeutics’ investment narrative.

Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.

What Is Structure Therapeutics' Investment Narrative?

To own Structure Therapeutics, you need to believe that its oral GLP‑1 and amylin programs can convert strong early obesity data into real, approvable drugs before cash and dilution pressures bite. The Genentech CT‑996 license slots into that story as validation and fresh non‑dilutive funding: US$100,000,000 upfront and potential royalties, without giving up control of Structure’s own pipeline. That may ease near term financing concerns and support key 2026 catalysts such as the FDA end‑of‑Phase 2 meeting for aleniglipron and the early read‑through from ACCG‑2671’s first‑in‑human study. At the same time, the stock has already had a very large 1 year move, there is still no revenue, losses are sizeable, and analysts do not yet agree tightly on fair value, so execution and valuation risk both remain front and center.

However, one key clinical and regulatory risk remains easy to overlook at first glance. Upon reviewing our latest valuation report, Structure Therapeutics' share price might be too optimistic.

Exploring Other Perspectives

Three fair value estimates from the Simply Wall St Community span roughly US$10 to just over US$100, underscoring how far apart individual views can be. Set that against a company with zero revenue, sizeable ongoing losses and a new but unproven Genentech licensing boost, and you can see why some market participants focus on upside catalysts while others worry more about execution risk. You are getting a wide spectrum of opinions, so it is worth weighing several of them before deciding how Structure fits into your portfolio.

Explore 3 other fair value estimates on Structure Therapeutics - why the stock might be worth less than half the current price!

Build Your Own Structure Therapeutics Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Structure Therapeutics research is our analysis highlighting 1 key reward and 4 important warning signs that could impact your investment decision.
• Our free Structure Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Structure Therapeutics' overall financial health at a glance.

Want Some Alternatives?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
• We've found 11 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
• Uncover the next big thing with financially sound penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.